Lineage Cell Therapeutics, Inc. Operating Lease, Expense
Lineage Cell Therapeutics, Inc. (LCTX) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $300.00K, a 0.00% change year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $300.00K, a 50.00% increase year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, expense for fiscal 2025 was $1.20M, a 9.09% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. operating lease, expense for fiscal 2024 was $1.10M, a 0.00% change from fiscal 2023.
- Lineage Cell Therapeutics, Inc. operating lease, expense for fiscal 2023 was $1.10M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-12 | $600.00K derived: sum of 2 quarters · filed 2026-05-12 | $900.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $600.00K derived: sum of 2 quarters · filed 2026-03-05 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M 10-K · filed 2026-03-05 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2026-08-06 | $900.00K 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $800.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-12 | $500.00K derived: sum of 2 quarters · filed 2026-05-12 | $800.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.10M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $500.00K derived: sum of 2 quarters · filed 2026-03-05 | $800.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2025-11-06 | $900.00K 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-12 | $600.00K 10-Q · filed 2025-08-12 | $800.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-13 | $500.00K derived: sum of 2 quarters · filed 2025-05-13 | $800.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.10M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $500.00K derived: sum of 2 quarters · filed 2025-03-10 | $800.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.10M 10-K · filed 2025-03-10 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-14 | $600.00K derived: sum of 2 quarters · filed 2024-11-14 | $900.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-08 | $600.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |